Low-dose transdermal hormone therapy does not interfere with the blood pressure of hypertensive menopausal women: a pilot study

Carvalho, Márcia Neves de; Nobre, Fernando; Mendes, Maria Carolina Santos; Reis, Rosana Maria dos; Ferriani, Rui Alberto; Sá, Marcos Felipe Silva de

doi:10.1097/mbp.0b013e32830d4b60

Cited by 14 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism responsible involves an increased angiotensin synthesis in the liver, leading to an enhanced angiotensin II generation and aldosterone secretion, ultimately causing sodium resorption and water retention [28]. No significant increase in BP values was seen in progestin-only pills users [29] or among postmenopausal women taking oral and transdermal hormone replacement therapy [30,31].…”

Section: Oral Contraceptive Pillsmentioning

confidence: 99%

Drug-induced hypertension: Know the problem to know how to deal with it

Masi

Uliana

Gesi

et al. 2019

Vascular Pharmacology

View full text Add to dashboard Cite

Section: Oral Contraceptive Pillsmentioning

confidence: 99%

Drug-induced hypertension: Know the problem to know how to deal with it

Masi

Uliana

Gesi

et al. 2019

Vascular Pharmacology

View full text Add to dashboard Cite

“…46–48 Hormone replacement therapy in clinical trials have failed to lower blood pressure or decrease cardiovascular diseases in postmenopausal females. 49–54 Therefore, 2-ME could be useful in treating hypertension, renal dysfunction, and end-organ damage in postmenopausal females; hypoestrogenemic premenopausal women; women with menstrual irregularities because of ovarian failure; and in men. However, further studies are required to determine its clinical use in these conditions and to elucidate the mechanism by which 2-ME minimizes hypertension caused by Ang II and in other models of experimental hypertension and associated pathogenesis in females with diminished estrogen levels and in intact males.…”

Section: Perspectivesmentioning

confidence: 99%

2-Methoxyestradiol Reduces Angiotensin II–Induced Hypertension and Renal Dysfunction in Ovariectomized Female and Intact Male Mice

et al. 2017

View full text Add to dashboard Cite

cytochrome P45 1B1 protects against angiotensin II-induced hypertension and associated cardiovascular changes in female mice, most likely via production of 2-methoxyestradiol. This study was conducted to determine if 2-methoxyestradiol ameliorates angiotensin II-induced hypertension, renal dysfunction, and end-organ damage in intact Cyp1b1−/−, ovariectomized female, and in Cyp1b1+/+ male mice. Ang II or vehicle was infused for 2 weeks and administered concurrently with 2-methoxyestradiol. Mice were placed in metabolic cages on day 12 of Ang II infusion for urine collection for 24 h. 2-Methoxyestradiol reduced angiotensin II-induced increases in systolic blood pressure, water consumption, urine output, and proteinuria in intact female Cyp1b1−/− and ovariectomized mice. 2-Methoxyestradiol also reduced Ang II-induced increase in blood pressure, water intake, urine output, and proteinuria in Cyp1b1+/+ male mice. Treatment with 2-methoxyestradiol attenuated Ang II-induced end-organ damage in intact Cyp1b1−/− and ovariectomized Cyp1b1+/+ and Cyp1b1−/− female mice, and Cyp1b1+/+ male mice. 2-Methoxyestradiol mitigated Ang II-induced increase in urinary excretion of angiotensinogen in intact Cyp1b1−/− and ovariectomized Cyp1b1+/+ and Cyp1b1−/− female mice but not in Cyp1b1+/+ male mice. The G-protein-coupled estrogen receptor 1 antagonist G-15 failed to alter Ang II-induced increases in blood pressure and renal function in Cyp1b1+/+ female mice. These data suggest that 2-methoxyestradiol reduces angiotensin II-induced hypertension and associated end-organ damage in intact Cyp1b1−/−, ovariectomized Cyp1b1+/+ and Cyp1b1−/− female mice, and Cyp1b1+/+ male mice independent of G protein-coupled estrogen receptor 1. Therefore, 2-methoxyestradiol could serve as a therapeutic agent for treating hypertension and associated pathogenesis in postmenopausal females, and in males.

show abstract

“…The results of the Women’s Health Initiative (WHI) [59] and HERS I and HERS II [60, 61] trials have not supported a role for HRT in primary or secondary prevention of cardiovascular disease. Similarly, HRT has not been shown to lower BP consistently in postmenopausal women [62–67]. The mode of delivery of HRT (whether oral or transdermal), the dose (whether high or low), and whether estradiol itself or another preparation is used may play a role in the BP effect.…”

Section: Role Of Estrogen/androgen Ratios In Hypertension In Womenmentioning

confidence: 99%

Hypertension in Postmenopausal Women

2012

View full text Add to dashboard Cite

Blood pressure is typically lower in premenopausal women than in men. However, after menopause, the prevalence of hypertension in women is higher than it is in men. Hypertension is a major risk factor for cardiovascular disease in women and men. Cardiovascular disease is the leading cause of death in women. Furthermore, there is evidence that blood pressure may not be as well-controlled in women as in men, despite the fact that most women adhere better to their therapeutic regimens and medications than do men, and have their blood pressures measured more frequently than do men. This review describes possible mechanisms by which blood pressure may be increased in postmenopausal women.

show abstract

Low-dose transdermal hormone therapy does not interfere with the blood pressure of hypertensive menopausal women: a pilot study

Abstract: Low-dose transdermal HT administered for 6 months was effective in improving climacteric symptoms and did not change BP values or circadian pattern in postmenopausal women with mild-to-moderate arterial hypertension taking antihypertensive medications.

Cited by 14 publications

References 30 publications

Drug-induced hypertension: Know the problem to know how to deal with it

Drug-induced hypertension: Know the problem to know how to deal with it

2-Methoxyestradiol Reduces Angiotensin II–Induced Hypertension and Renal Dysfunction in Ovariectomized Female and Intact Male Mice

Hypertension in Postmenopausal Women

Contact Info

Product

Resources

About